Future studies to evaluate the in vivo efficacy of CAR/CXCR5 immunotherapy must address multiple complexities under active study in the cancer field (56, 83, 84), plus others distinct for HIV (60, 85, 86). The gene discussed is CXCR5; the disease is cancer.